EnzeKangtai Biotechnology Completes Tens of Millions of RMB Series A++ Financing, WinX Capital Acts as Exclusive Financial Advisor

VCBeat (WeChat: vcbeat) has learned that recently,Beijing Enze Kangtai Biotechnology Co., Ltd. (hereinafter referred to as “ECHO BIOTECH”), an innovative high-tech company dedicated to the development and clinical translation of exosome technologies, has completed a tens-of-millions-yuan A++ round of financing. This round was jointly participated in by ZBJL CAPITAL and Yanrui Investment, with existing shareholder Baidu Ventures continuing its support. WinX Capital served as the exclusive financial advisor for this financing round.The funds raised in this financing round will be primarily used to iterate the engineered exosome technology platform and expand its solutions, empowering industry development and accelerating the clinical translation of engineered exosome therapies.

Exosome-based therapeutic products have been included in the 14th Five-Year Plan for Bioeconomy Development, providing policy direction for the industry’s robust growth. As an industry leader, ECHO BIOTECH prioritizes independent innovation and has established a research and development team primarily composed of highly educated professionals since its inception. The company has assembled a multidisciplinary team with expertise in molecular biology, cell biology, structural biology, virology, immunology, and bioinformatics, alongside experienced pharmaceutical R&D and CMC teams, thereby possessing strong capabilities in exosome research and independent innovation.

The company has established a mature platform for exosome research and therapeutic translation, forged collaborations with over 100 leading hospitals in China, co-authored more than 100 high-impact SCI papers, and participated in the development of expert consensus statements on exosomes. Additionally, it jointly organizes the “Exosome Grand Lecture Series” with the Chinese Society for Extracellular Vesicles (CSEV) to jointly promote the vigorous development of exosome technology and its translational applications.

ECHO BIOTECH is dedicated to empowering clinical research and accelerating clinical translation by providing systematic solutions for exosome research and therapeutic translation, establishing itself as a premium partner in the exosome industry for research and therapeutic translation. The company’s business operations are divided into two segments:

● On one hand, leveraging a platform with independent intellectual property rights to provide leading life science research services: the exosome omics platform—Exoomics^®Core High-Throughput Multi-Omics Solutions and Engineered Exosome Modification Platform—ModiExo^®core basic research solutions, and continuously launch efficient exosome research tools tailored to customer needs;

● On the other hand, it is based on Echosome, an engineered exosome platform built upon core intellectual property^®Empowering the R&D of innovative exosome-based drugs, we have established a 3,000-square-meter GMP pilot plant for exosomes and developed mature exosome production processes and quality characterization systems. We provide CRO services, including engineered exosome vector design and development as well as PCC development for engineered exosome therapeutics, along with CDMO services for engineered exosomes.

Upon the completion of this round of financing,Kong Guanyi, Founder of ECHO BIOTECHStatement: ECHO BIOTECH sincerely appreciates the recognition and support from various professional investment institutions. Since its inception, the company has firmly believed in the promising applications of exosomes in the fields of disease biomarkers and drug delivery. As a cutting-edge global innovation, exosome technology still faces several critical technical challenges that need to be addressed during its translation from concept to application (from 0 to 1). Through years of technological refinement and accumulation, ECHO BIOTECH has established an R&D and therapeutic translation platform for exosomes with core competitiveness. Moving forward, the company will continue to focus on frontier research in the exosome field, deepen the development of underlying technologies, concentrate on the iterative advancement of engineered exosome platform technologies and compliant industrial-scale production of exosomes, and consistently deliver high-quality exosome technical services and engineered exosome drug delivery solutions.

Tian Xiaoling, Investment Director of ZBJL CAPITALIt is stated that exosomes are naturally evolved nanocarriers. Due to their superior physicochemical and biological properties, they possess advantages unavailable to other drug delivery vehicles, offering broader market prospects and development potential than antibodies, gene therapies, or cell therapies. ECHO BIOTECH has established a comprehensive product and business layout centered on the “understanding, engineering, and application of exosomes.” By dedicating itself to in-depth development in the exosome field, the company has achieved breakthroughs in engineered exosome modification, efficient cargo loading and delivery, and CMC standardization. Its series of engineered exosome products have been fully launched, and a 3,000-square-meter GMP pilot-scale workshop for exosomes has been completed, laying a solid foundation for the development of innovative exosome-based drugs. As a key driver in the exosome industry, ECHO BIOTECH looks forward to extensive collaboration with peer pharmaceutical companies to jointly promote the advancement of exosome therapeutics.

Li Zhe, Partner at Yanrui InvestmentIt has been ten years since the Nobel Prize was awarded for the discovery of vesicle transport mechanisms in 2013. During this period, ECHO BIOTECH, together with biotechnology companies worldwide engaged in exosome development, has continuously worked to advance the field toward maturity. Through ongoing practice, the exceptional plasticity and safety of exosomes as drug delivery vehicles have been revealed, offering greater possibilities for human disease treatment. As an advanced platform for exosome research and therapeutic translation, ECHO BIOTECH fully demonstrates its leading capabilities in technology development and engineering translation.

An Feng, Head of Healthcare Investments at Baidu VenturesIt was stated that the healthcare and pharmaceutical industry experienced a trough over the past year, with some companies at the forefront of international innovative technologies encountering development difficulties. ECHO BIOTECH’s ability to secure financing again in the current environment is attributable to the dual-engine drive of its innovative technology platform and innovative business model. We remain optimistic about the clinical translation prospects of the exosome industry and confident that ECHO BIOTECH will continue to fulfill its role as a leading enterprise in the industrialization of exosomes.

Dr. Guowen Zou, Founding Partner of WinX CapitalStatement: We extend our sincere gratitude to the ECHO BIOTECH team for their trust in WinX Capital, and to all new and existing shareholders for their strong support. As a leading enterprise with forward-looking strategic layout and sustained innovation capabilities in the exosome sector, ECHO BIOTECH was among the first in China to enter this innovative field and has built a professional, comprehensive, and pragmatic talent team. We are confident that through continuous refinement and iteration of exosome technologies, ECHO BIOTECH will achieve ongoing breakthroughs and lead the development of the exosome industry.

ZBJL CAPITALFounded in 2013, ZBJL CAPITAL focuses its investments on next-generation information technology, biopharmaceuticals, and new energy. Adhering to the investment philosophy of “being rooted in technology and practicing value,” the firm emphasizes the scarce value generated by technological innovation. It avoids following trends or blindly conforming, instead continuously identifying potential unicorn companies with high technical barriers and strong core competitiveness. By empowering portfolio companies through both capital and resources, ZBJL CAPITAL supports the development of China’s technology enterprises, creates value, and benefits humanity and society.

Yanrui Investment was established in 2015 as an equity investment firm specializing in early-stage and growth-stage investments in the semiconductor and biopharmaceutical sectors. The core investment team at Yanrui Investment boasts extensive operational experience, nearly two decades of investment expertise, and abundant corporate management resources. Currently, Yanrui Investment manages assets totaling nearly RMB 1 billion, with a portfolio of over ten companies spanning the biopharmaceutical, new materials, and semiconductor industries. The firm is committed to empowering entrepreneurs and creating value for investors.

Baidu Ventures is an independent venture capital firm initiated by Baidu Group, with three funds in USD and RMB totaling over $700 million. Focusing primarily on early-stage pioneer companies in emerging technologies, Baidu Ventures is dedicated to key sectors including healthcare and livelihood, smart transportation, and technology extension. Leveraging strong support and resource sharing from Baidu Group, Baidu Ventures has strategically positioned itself in the field of artificial intelligence. Its current investment portfolio spans new energy vehicles, life sciences, enterprise services, smart cities, Web 3.0, and XR hardware and software devices.

WinX Capital is a leading investment bank in China’s healthcare sector. Headquartered in Beijing and Shanghai, it covers more than 3,000 active institutional investors and industrial groups. From 2020 to 2022, WinX Capital was consecutively recognized by Qimingpian & Xinsheng Chuangfu as “Top 2 Best Financial Advisors in Healthcare (2021–2022),” “Top 4 Best Financial Advisory Firms in Healthcare (2020),” “Top 10 Best Financial Advisors – Active List (2021),” “Top 6 Best Financial Advisors – Comprehensive List (Mid-2022),” and “Top 7 Best Financial Advisors – Active List (Mid-2022).” It was also ranked among the “Top 5 Most Promising Emerging Investment Banks in China (WISE2020/2021)” by 36Kr, and named “Top 5 Healthcare Financial Advisor of the Year” at VCBeat’s 2022 “Pengcheng Awards.”